Bonesupport Holding AB (publ)
BOEUF
Other OTC20.49
USD
- -
- -
ISIN
SE0009858152
Return %
Stock
S&P500
1Y
-38.85
17.85
3Y
30.15
64.56
5Y
196.88
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Torbjorn Skold
- Full Time Employees
- 160
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Scheelevägen 19 Lund SN Sweden 223 70
- IPO Date
- Jul 8, 2020
- Website
- bonesupport.com
- Similar Companies
- Business
- Bonesupport Holding AB (publ) is a Sweden-based orthobiologics company specializing in the development and commercialization of injectable bioceramic bone graft substitutes designed to treat bone voids and disorders. The company’s core product portfolio is based on its proprietary CERAMENT technology platform, which includes CERAMENT BVF (Bone Void Filler), CERAMENT G (a gentamicin-eluting bone graft substitute), and CERAMENT V (a vancomycin-eluting product). These products are radiopaque, injectable, osteoconductive, and remodel to host bone while capable of local drug delivery. The company targets conditions including trauma, revision arthroplasty, chronic osteomyelitis, diabetic foot infections, and foot and ankle surgery. Its products are marketed across Europe, North America, India, Malaysia, Oman, and Singapore. Founded in 1999 and headquartered in Lund, Sweden, Bonesupport operates through two geographic segments: North America, and Europe and Rest of the World. Recent strategic developments include strong sales growth supported by expansion in the U.S. and the launch of new clinical evidence such as the CeraHip study, which enhances entry into the revision arthroplasty segment. The company is actively expanding its commercial footprint using a hybrid model in additional markets like Norway and Austria, with investments expected to be cash flow neutral within two years. In 2024 and 2025, Bonesupport posted significant revenue growth, with over 40% sales growth guidance maintained for 2025, reflecting robust U.S. market performance and expanding clinical adoption. Additionally, the company has shifted the regulatory pathway for its CERAMENT V product to the De Novo process to support its market launch for treating bone infections. Bonesupport continues to invest in expanding its product portfolio and geographic reach, including potential ventures into the spine segment by the end of 2025, reinforcing its position in the orthobiologics field as a leader in advanced bone treatment solutions.
Bonesupport Holding AB (publ) (BOEUF) Q2 2026 Earnings Call Transcript
Bonesupport Holding AB (publ) (BOEUF) Q1 2026 Earnings Call Transcript
Bonesupport Holding AB (publ) (BOEUF) Q4 2025 Earnings Call Transcript